{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:30:51Z","timestamp":1794022251023,"version":"4.8.0"},"reference-count":43,"publisher":"BMJ","issue":"17","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2016,4,14]]},"published-print":{"date-parts":[[2016,9,1]]},"abstract":"<jats:p>Inhibition of neurohumoural pathways such as the renin angiotensin aldosterone and sympathetic nervous systems is central to the understanding and treatment of heart failure (HF). Conversely, until recently, potentially beneficial augmentation of neurohumoural systems such as the natriuretic peptides has had limited therapeutic success. Administration of synthetic natriuretic peptides has not improved outcomes in acute HF but modulation of the natriuretic system through inhibition of the enzyme that degrades natriuretic (and other vasoactive) peptides, neprilysin, has proven to be successful. After initial failures with neprilysin inhibition alone or dual neprilysin-angiotensin converting enzyme (ACE) inhibition, the Prospective comparison of angiotensin receptor neprilysin inhibitor (ARNI) with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) trial demonstrated that morbidity and mortality can be improved with the angiotensin receptor blocker neprilysin inhibitor sacubitril\/valsartan (formerly LCZ696). In comparison to the ACE inhibitor enalapril, sacubitril\/valsartan reduced the occurrence of the primary end point (cardiovascular death or hospitalisation for HF) by 20% with a 16% reduction in all-cause mortality. These findings suggest that sacubitril\/valsartan should replace an ACE inhibitor or angiotensin receptor blocker as the foundation of treatment of symptomatic patients (NYHA II\u2013IV) with HF and a reduced ejection fraction. This review will explore the background to neprilysin inhibition in HF, the results of the PARADIGM-HF trial and offer guidance on how to use sacubitril\/valsartan in clinical practice.<\/jats:p>","DOI":"10.1136\/heartjnl-2014-306775","type":"journal-article","created":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T02:49:02Z","timestamp":1463971742000},"page":"1342-1347","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":159,"title":["The neprilysin pathway in heart failure: a review and guide on the use of sacubitril\/valsartan"],"prefix":"10.1136","volume":"102","clinical-trial-number":[{"clinical-trial-number":"nct01920711","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02661217","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Pardeep S","family":"Jhund","sequence":"first","affiliation":[{"name":"BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,5,20]]},"reference":[{"key":"2025092002534725000_102.17.1342.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501"},{"key":"2025092002534725000_102.17.1342.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301"},{"key":"2025092002534725000_102.17.1342.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010713"},{"key":"2025092002534725000_102.17.1342.4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.812172"},{"key":"2025092002534725000_102.17.1342.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.09.021"},{"key":"2025092002534725000_102.17.1342.6","doi-asserted-by":"publisher","DOI":"10.1042\/CS20030366"},{"key":"2025092002534725000_102.17.1342.7","doi-asserted-by":"publisher","DOI":"10.1007\/BF01726570"},{"key":"2025092002534725000_102.17.1342.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.12.1531"},{"key":"2025092002534725000_102.17.1342.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100171"},{"key":"2025092002534725000_102.17.1342.10","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-08-0130"},{"key":"2025092002534725000_102.17.1342.11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.19.7580"},{"key":"2025092002534725000_102.17.1342.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90714-9"},{"key":"2025092002534725000_102.17.1342.13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/0140-6736(90)90595-V","article-title":"Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure","volume":"335","author":"Kahn","year":"1990","journal-title":"Lancet"},{"key":"2025092002534725000_102.17.1342.14","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199207000-00002"},{"key":"2025092002534725000_102.17.1342.15","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.71.6.1501"},{"key":"2025092002534725000_102.17.1342.16","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12053"},{"key":"2025092002534725000_102.17.1342.17","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.23.2323"},{"key":"2025092002534725000_102.17.1342.18","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000029801.86489.50"},{"key":"2025092002534725000_102.17.1342.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61966-8"},{"key":"2025092002534725000_102.17.1342.20","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009343932"},{"key":"2025092002534725000_102.17.1342.21","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e318210fc7e"},{"key":"2025092002534725000_102.17.1342.22","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hft052"},{"key":"2025092002534725000_102.17.1342.23","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.115"},{"key":"2025092002534725000_102.17.1342.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"2025092002534725000_102.17.1342.25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv186"},{"key":"2025092002534725000_102.17.1342.26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013748"},{"key":"2025092002534725000_102.17.1342.27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv330"},{"key":"2025092002534725000_102.17.1342.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.08.878"},{"key":"2025092002534725000_102.17.1342.29","unstructured":"Guidance for industry\u2014Providing evidence of effectiveness for human drug and biological products. U.S. Department of Health and Human Services, May 1998. (cited 30 September 2015). http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/ucm078749.pdf"},{"key":"2025092002534725000_102.17.1342.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.10.014"},{"key":"2025092002534725000_102.17.1342.31","doi-asserted-by":"crossref","unstructured":"Senni M , McMurray JJV , Wachter R , et al . Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomised comparison of two up-titration regimens. Eur J Heart Fail 2016 May 12. doi: 10.1002\/ejhf.548.","DOI":"10.1002\/ejhf.548"},{"key":"2025092002534725000_102.17.1342.32","unstructured":"U.S. Food and Drug Administration. ENTRESTO (sacubitril and valsartan). Highlights of prescribing information. (cited 30 September 2015). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207620Orig1s000lbl.pdf"},{"key":"2025092002534725000_102.17.1342.33","unstructured":"European Medicines Agency. Entresto: EPAR Product information. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004062\/WC500197536.pdf"},{"key":"2025092002534725000_102.17.1342.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)06031-5"},{"key":"2025092002534725000_102.17.1342.35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.109.849299"},{"key":"2025092002534725000_102.17.1342.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.10.064"},{"key":"2025092002534725000_102.17.1342.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2016.02.007"},{"key":"2025092002534725000_102.17.1342.38","unstructured":"(NICE) NI for CE. Appraisal consultation document Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction. https:\/\/www.nice.org.uk\/guidance\/GID-TAG516\/documents\/appraisal-consultation-document"},{"key":"2025092002534725000_102.17.1342.39","unstructured":"Scottish Medicines Consortium. Product details sacubitril\/valsartan. https:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/1132_16_sacubitril_valsartan_Entresto"},{"key":"2025092002534725000_102.17.1342.40","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht463"},{"key":"2025092002534725000_102.17.1342.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61227-6"},{"key":"2025092002534725000_102.17.1342.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2014.10.022"},{"key":"2025092002534725000_102.17.1342.43","unstructured":"Scottish Intercollegiate Guidelines Network. Management of chronic heart failure. 2016 . http:\/\/www.sign.ac.uk\/guidelines\/fulltext\/147\/index.html"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2014-306775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:53:52Z","timestamp":1758362032000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2014-306775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,20]]},"references-count":43,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2016,8,11]]},"published-print":{"date-parts":[[2016,9,1]]}},"alternative-id":["10.1136\/heartjnl-2014-306775"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2014-306775","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,20]]}}}